ClinicalTrials.gg
CompletedNCT01778049Updated Apr 4, 2016Results posted

Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes

A Phase 3 interventional study of BI 10773 and BI 10773 Placebo in Diabetes Mellitus, Type 2, sponsored by Boehringer Ingelheim. Completed at 114 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-04-04.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
708
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 130 studies testing empagliflozin in Diabetes Mellitus, Type 2 — 18 open to participants now, 19 under way, 1 of them phase 3. empagliflozin · Diabetes Mellitus, Type 2.

Enrollment
18th of 130
708 · median 79
Started
2013
with 3 others
Phase 3
28 of 130
1 open now
Registered
27th of 130
by date
Lead sponsor
37 of 130
Boehringer Ingelheim

Among the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2, this one is the 18th largest by enrollment, is one of 4 that started in 2013, is one of 28 in phase 3, and was the 27th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

18 of the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2 are open now, in 10 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 18 open studies →

About empagliflozin

empagliflozin: first FDA approval 2014 (JARDIANCE), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 130 studies testing empagliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The objective of the study is to investigate the efficacy, safety and tolerability of linagliptin 5 mg qd compared to placebo given for 24 weeks in inadequately controlled T2DM patients on empagliflozin 10 mg or 25 mg and maximum tolerated dose of metformin. The primary objective of efficacy evaluation is planned after 24 weeks of treatment. The study is designed to show superiority of the combination of empagliflozin and linagliptin over empagliflozin alone.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed and dated ICF ( Form)
  2. Male or female on diet and exercise regime and on stable background metformin > or equal to 1500 mg or maximun dose according to local label
  3. (Glicoslated ) > or equal to 8% and \< or equal to 10.5 % at Visit 1
  4. HbA1c > or equal to 7 and \< or equal to 10.5 at Visit 4
  5. Age > or equal to 18 years
  6. (Body Mass Index) \< or equal to 45

Exclusion criteria

Exclusion criteria:

  1. Uncontrolled hyperglycemia during open label period and placebo add on "run-in" period
  2. Use of any other antidiabetic
  3. Renal function below 60 ml/min/1.73 m2
  4. Antiobesity drugs or aggresive diets
  5. Gastorintestinal surgeries
  6. Current systemic or uncontrolled endocrine disorders other than Diabetes Type 2
  7. Acute coronary syndrome and stroke within 3 months of
  8. Known allergies to DPP-IV (Dypeptidil Peptidase IV) or SGLT-2 (Sodium Glucose Transporter 2) inhibitors
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
708 participants (actual)

Study arms

  • Experimental
    Empagliflozin 10 mg dose

    Empagliflozin open label treatment period

    Drug: BI 10773

  • Experimental
    Placebo add on 10 mg dose

    Empagliflozin / Linagliptin 10/5 mg Dose FDC placebo add on run-in

    Drug: BI 10773 / BI 1356 Placebo · Drug: BI 10773

  • Experimental
    Empagliflozin/Linagliptin 25/5 mg Dose

    Empagliflozin / Linagliptin 25/5 mg Dose FDC active

    Drug: BI 10773 / BI 1356 · Drug: BI 10773 Placebo

  • Experimental
    Empagliflozin/Linagliptin 10/5 mg Dose.

    Empagliflozin / Linagliptin 10/5 mg Dose FDC placebo

    Drug: BI 10773 / BI 1356 Placebo · Drug: BI 10773

  • Experimental
    Empagliflozin/Linagliptin 10/5 mg Dose

    Empagliflozin / Linagliptin 10/5 mg Dose FDC active

    Drug: BI 10773 Placebo · Drug: BI 10773 / BI 1356

  • Experimental
    Empagliflozin 25 mg dose

    Empagliflozin open label treatment period

    Drug: BI 10773

  • Experimental
    Empagliflozin/Linagliptin 25/5 mg Dose.

    Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo

    Drug: BI 10773 · Drug: BI 10773 / BI 1356 Placebo

  • Experimental
    Placebo add on 25 mg dose

    Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo add on run-in

    Drug: BI 10773 · Drug: BI 10773 / BI 1356 Placebo

Interventions

  • Empagliflozin active

  • DrugBI 10773 Placebo

    Empagliflozin placebo

  • DrugBI 10773 / BI 1356

    Drug pages: Empagliflozin · Linagliptin

    Empagliflozin / Linagliptin 25/5 mg Dose FDC active

  • Empagliflozin active

  • DrugBI 10773 / BI 1356

    Drug pages: Empagliflozin · Linagliptin

    Empagliflozin / Linagliptin 10/5 mg Dose FDC active

  • DrugBI 10773 / BI 1356 Placebo

    Empagliflozin / Linagliptin 10/5 mg Dose placebo FDC

  • Empagliflozin active

  • Empagliflozin active

  • Empagliflozin active

  • DrugBI 10773 / BI 1356 Placebo

    Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo

  • DrugBI 10773 Placebo

    Empagliflozin placebo

  • DrugBI 10773 / BI 1356 Placebo

    Empagliflozin / Linagliptin 10/5 mg Dose FDC placebo

  • Empagliflozin active

  • DrugBI 10773 / BI 1356 Placebo

    Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo

06

What researchers measure

Primary outcomes

  1. Change From Baseline of HbA1c After 24 Weeks of Treatment.

    Change from baseline in Glycated haemoglobin (HbA1c) \[%\] after 24 weeks of treatment with double-blind trial medication, i.e. HbA1c change from baseline at Week 24. The term "baseline" was not used to refer to measurements prior to the administration of open-label medication. Such measurements were referred to as "pre-treatment". Analyses of change from pre-treatment used the last value before first administration of open-label medication as point of reference. Observed Case (OC): This method analyse only available data that were observed while patients were on treatment, i.e., excluding the missing data. All values measured after rescue medication taken were set to missing. Full Analysis Set (FAS): Includes all patients in the Treated set who had a baseline HbA1c assessment and at least 1 on-treatment HbA1c assessment during the double-blind part of the trial.

    Time frame: Baseline and 24 weeks

Secondary outcomes

  1. Fasting Plasma Glucose (FPG) Change From Baseline at 24 Weeks.

    Change from baseline FPG (mmol/L) after 24 weeks of treatment with double-blind trial medication, i.e. FPG change from baseline at Week 24.

    Time frame: Baseline and 24 weeks

07

Results

Posted Apr 4, 2016

Participant flow

Subjects randomised to 16 week(wk) open-label (OL) treatment with either empagliflozin (empa) 25 or empa 10 treatment, thereafter subjects entered to 1 wk open label placebo (Plc) add-on period in order to complete further eligibility evaluations before being randomised into 1 of the 24 wk double-blind treatment groups.

Open Label Treatment Period
Participant flow — Open Label Treatment Period
MilestoneEmpa 10 mg OLEmpa 25 mg OLLina5 (E10)Plc (E10)Lina5 (E25)Plc (E25)
Started3543550000
Completed2562260000
Not completed981290000
Withdrew: Adverse event5150000
Withdrew: Lack of efficacy110000
Withdrew: Protocol violation550000
Withdrew: Lost to follow-up430000
Withdrew: Withdrawal by subject4100000
Withdrew: Not treated210000
Withdrew: Other reason not defined above77940000
Double Blind Treatment Period
Participant flow — Double Blind Treatment Period
MilestoneEmpa 10 mg OLEmpa 25 mg OLLina5 (E10)Plc (E10)Lina5 (E25)Plc (E25)
Started00126130114112
Completed00111118102105
Not completed001512127
Withdrew: Adverse event004532
Withdrew: Lack of efficacy000001
Withdrew: Protocol violation002000
Withdrew: Lost to follow-up004152
Withdrew: Withdrawal by subject001201
Withdrew: Not treated000220
Withdrew: Other reason not defined above004221

Outcome measures

PrimaryChange From Baseline of HbA1c After 24 Weeks of Treatment.

Change from baseline in Glycated haemoglobin (HbA1c) \[%\] after 24 weeks of treatment with double-blind trial medication, i.e. HbA1c change from baseline at Week 24. The term "baseline" was not used to refer to measurements prior to the administration of open-label medication. Such measurements were referred to as "pre-treatment". Analyses of change from pre-treatment used the last value before first administration of open-label medication as point of reference. Observed Case (OC): This method analyse only available data that were observed while patients were on treatment, i.e., excluding the missing data. All values measured after rescue medication taken were set to missing. Full Analysis Set (FAS): Includes all patients in the Treated set who had a baseline HbA1c assessment and at least 1 on-treatment HbA1c assessment during the double-blind part of the trial.

Time frame:
Baseline and 24 weeks
Reported as:
Least squares mean · Percentage of HbA1c
Change From Baseline of HbA1c After 24 Weeks of Treatment.
Percentage of HbA1cLina5 (E10)Plc (E10)Lina5 (E25)Plc (E25)
Change From Baseline of HbA1c After 24 Weeks of Treatment.-0.53 ± 0.07-0.21 ± 0.07-0.58 ± 0.07-0.10 ± 0.07
Statistical analysis
  • Lina5 (E10) vs Plc (E10) · Mixed Model Repeated Measure (MMRM) · p = 0.0013 · Mean difference (final values): -0.32 · 95% CI -0.52 to -0.13Mean Difference (Final Values) is actually the adjusted mean difference calculated as lina5 (E10) minus Plc (E10) value.
  • Lina5 (E25) vs Plc (E25) · MMRM · p = <0.0001 · Mean difference (final values): -0.47 · 95% CI -0.66 to -0.28Mean Difference (Final Values) is actually the adjusted mean difference value calculated as lina5 (E25) minus Plc (E25).
SecondaryFasting Plasma Glucose (FPG) Change From Baseline at 24 Weeks.

Change from baseline FPG (mmol/L) after 24 weeks of treatment with double-blind trial medication, i.e. FPG change from baseline at Week 24.

Time frame:
Baseline and 24 weeks
Reported as:
Least squares mean · mmol/L
Fasting Plasma Glucose (FPG) Change From Baseline at 24 Weeks.
mmol/LLina5 (E10)Plc (E10)Lina5 (E25)Plc (E25)
Fasting Plasma Glucose (FPG) Change From Baseline at 24 Weeks.-0.44 ± 0.180.21 ± 0.18-0.68 ± 0.15-0.24 ± 0.15
Statistical analysis
  • Lina5 (E10) vs Plc (E10) · MMRM · p = 0.0103 · Mean difference (final values): -0.65 · 95% CI -1.15 to -0.16Mean Difference (Final Values) is actually the adjusted mean difference value calculated as lina5 (E10) minus Plc (E10).
  • Lina5 (E25) vs Plc (E25) · MMRM · p = 0.0452 · Mean difference (final values): -0.44 · 95% CI -0.87 to -0.01Mean Difference (Final Values) is actually the adjusted mean difference value calculated as lina5 (E25) minus Plc (E25).

Adverse events

Collected over From first drug administration until 7 days after the last drug administration, up to 212 days (OL treatment period) and 205 days (double blind treatment period).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Empa 10 mg OL—12/352 (3.4%)47/352 (13.4%)
Empa 25 mg OL—12/354 (3.4%)38/354 (10.7%)
Lina5 (E10)—4/126 (3.2%)22/126 (17.5%)
Plc (E10)—5/128 (3.9%)10/128 (7.8%)
Lina5 (E25)—3/112 (2.7%)18/112 (16.1%)
Plc (E25)—4/112 (3.6%)21/112 (18.8%)
Most frequent serious events
Showing 10 of 52
Most frequent serious events
EventEmpa 10 mg OLEmpa 25 mg OLLina5 (E10)Plc (E10)Lina5 (E25)Plc (E25)
OsteomyelitisInfections and infestations0/3520/3540/1260/1280/1122/112
Atrial flutterCardiac disorders0/3520/3540/1260/1281/1120/112
TachycardiaCardiac disorders0/3520/3540/1260/1281/1120/112
Intestinal polypGastrointestinal disorders0/3520/3540/1260/1280/1121/112
FallInjury, poisoning and procedural complications1/3520/3540/1260/1280/1121/112
HaemarthrosisMusculoskeletal and connective tissue disorders0/3520/3540/1260/1280/1121/112
Pharyngeal lesionRespiratory, thoracic and mediastinal disorders0/3520/3540/1260/1281/1120/112
Dermatitis bullousSkin and subcutaneous tissue disorders0/3520/3540/1260/1281/1120/112
Dyshidrotic eczemaSkin and subcutaneous tissue disorders0/3520/3540/1260/1281/1120/112
Extremity necrosisVascular disorders0/3520/3540/1260/1280/1121/112
Most frequent other events
Most frequent other events
EventEmpa 10 mg OLEmpa 25 mg OLLina5 (E10)Plc (E10)Lina5 (E25)Plc (E25)
Urinary tract infectionInfections and infestations16/35223/35410/1266/12811/1127/112
NasopharyngitisInfections and infestations17/3525/3548/1263/1282/1128/112
Lipase increasedInvestigations15/35210/3544/1261/1287/1127/112

Baseline characteristics

The open-label treated set (OLTS) was used for the open label treatment period. This analysis set consisted of all patients who received at least 1 dose of open-label treatment during the trial.

Age, Continuous
Age, Continuous(Years)Empa 10 mg OLEmpa 25 mg OLTotal
Mean57.0 ± 9.656.7 ± 9.956.8 ± 9.8
Sex: Female, Male
Sex: Female, Male(Participants)Empa 10 mg OLEmpa 25 mg OLTotal
Female145161306
Male207193400
08

Study locations

114 sites
  • 1275.10.01019 Boehringer Ingelheim Investigational Site
    Chino, California, United States
  • 1275.10.01008 Boehringer Ingelheim Investigational Site
    Huntington Beach, California, United States
  • 1275.10.01003 Boehringer Ingelheim Investigational Site
    San Diego, California, United States
  • 1275.10.01024 Boehringer Ingelheim Investigational Site
    San Diego, California, United States
  • 1275.10.01002 Boehringer Ingelheim Investigational Site
    Sylmar, California, United States
  • 1275.10.01011 Boehringer Ingelheim Investigational Site
    Miami, Florida, United States
  • 1275.10.01009 Boehringer Ingelheim Investigational Site
    Orlando, Florida, United States
  • 1275.10.01023 Boehringer Ingelheim Investigational Site
    Oviedo, Florida, United States
  • 1275.10.01006 Boehringer Ingelheim Investigational Site
    Tamarac, Florida, United States
  • 1275.10.01017 Boehringer Ingelheim Investigational Site
    Conyers, Georgia, United States
  • 1275.10.01016 Boehringer Ingelheim Investigational Site
    Snellville, Georgia, United States
  • 1275.10.01012 Boehringer Ingelheim Investigational Site
    Avon, Indiana, United States
  • 1275.10.01013 Boehringer Ingelheim Investigational Site
    Muncie, Indiana, United States
  • 1275.10.01010 Boehringer Ingelheim Investigational Site
    Elkton, Maryland, United States
  • 1275.10.01001 Boehringer Ingelheim Investigational Site
    Stevensville, Michigan, United States
  • 1275.10.01007 Boehringer Ingelheim Investigational Site
    Salisbury, North Carolina, United States
  • 1275.10.01005 Boehringer Ingelheim Investigational Site
    Bismarck, North Dakota, United States
  • 1275.10.01020 Boehringer Ingelheim Investigational Site
    Oklahoma City, Oklahoma, United States
  • 1275.10.01022 Boehringer Ingelheim Investigational Site
    Pittsburgh, Pennsylvania, United States
  • 1275.10.01021 Boehringer Ingelheim Investigational Site
    Union, South Carolina, United States
  • 1275.10.01014 Boehringer Ingelheim Investigational Site
    North Richland Hills, Texas, United States
  • 1275.10.01018 Boehringer Ingelheim Investigational Site
    Draper, Utah, United States
  • 1275.10.01015 Boehringer Ingelheim Investigational Site
    Richmond, Virginia, United States
  • 1275.10.01025 Boehringer Ingelheim Investigational Site
    Virginia Beach, Virginia, United States
  • 1275.10.54005 Boehringer Ingelheim Investigational Site
    Caba, Argentina
  • 1275.10.54012 Boehringer Ingelheim Investigational Site
    Caba, Argentina
  • 1275.10.54002 Boehringer Ingelheim Investigational Site
    Capital Federal, Argentina
  • 1275.10.54007 Boehringer Ingelheim Investigational Site
    Capital Federal, Argentina
  • 1275.10.54013 Boehringer Ingelheim Investigational Site
    Capital Federal, Argentina
  • 1275.10.54006 Boehringer Ingelheim Investigational Site
    Cordoba, Argentina
  • 1275.10.54008 Boehringer Ingelheim Investigational Site
    Cordoba, Argentina
  • 1275.10.54011 Boehringer Ingelheim Investigational Site
    Córdoba, Argentina
  • 1275.10.54003 Boehringer Ingelheim Investigational Site
    Godoy Cruz, Mendoza, Argentina
  • 1275.10.54009 Boehringer Ingelheim Investigational Site
    Mar del Plata, Argentina
  • 1275.10.54004 Boehringer Ingelheim Investigational Site
    Salta, Argentina
  • 1275.10.54001 Boehringer Ingelheim Investigational Site
    San Isidro, Argentina
  • 1275.10.54010 Boehringer Ingelheim Investigational Site
    Zarate, Argentina
  • 1275.10.61008 Boehringer Ingelheim Investigational Site
    Cardiff, New South Wales, Australia
  • 1275.10.61002 Boehringer Ingelheim Investigational Site
    East Ringwood, Victoria, Australia
  • 1275.10.61001 Boehringer Ingelheim Investigational Site
    Heidelberg Heights, Victoria, Australia
  • 1275.10.61009 Boehringer Ingelheim Investigational Site
    Mirrabooka, Western Australia, Australia
  • 1275.10.02004 Boehringer Ingelheim Investigational Site
    Edmonton, Alberta, Canada
  • 1275.10.02001 Boehringer Ingelheim Investigational Site
    Red Deer, Alberta, Canada
  • 1275.10.02003 Boehringer Ingelheim Investigational Site
    Chilliwack, British Columbia, Canada
  • 1275.10.02009 Boehringer Ingelheim Investigational Site
    Coquitlam, British Columbia, Canada
  • 1275.10.02012 Boehringer Ingelheim Investigational Site
    Vancouver, British Columbia, Canada
  • 1275.10.02006 Boehringer Ingelheim Investigational Site
    Winnipeg, Manitoba, Canada
  • 1275.10.02008 Boehringer Ingelheim Investigational Site
    Winnipeg, Manitoba, Canada
  • 1275.10.02005 Boehringer Ingelheim Investigational Site
    Moncton, New Brunswick, Canada
  • 1275.10.02013 Boehringer Ingelheim Investigational Site
    Burlington, Ontario, Canada
  • 1275.10.02002 Boehringer Ingelheim Investigational Site
    Strathroy, Ontario, Canada
  • 1275.10.02007 Boehringer Ingelheim Investigational Site
    Sudbury, Ontario, Canada
  • 1275.10.02011 Boehringer Ingelheim Investigational Site
    Drummondville, Quebec, Canada
  • 1275.10.02010 Boehringer Ingelheim Investigational Site
    Montreal, Quebec, Canada
  • 1275.10.34014 Boehringer Ingelheim Investigational Site
    Ávila, El Salvador
  • 1275.10.49007 Boehringer Ingelheim Investigational Site
    Asslar, Germany
  • 1275.10.49014 Boehringer Ingelheim Investigational Site
    Berlin, Germany
  • 1275.10.49016 Boehringer Ingelheim Investigational Site
    Elsterwerda, Germany
  • 1275.10.49012 Boehringer Ingelheim Investigational Site
    Hamburg, Germany
  • 1275.10.49005 Boehringer Ingelheim Investigational Site
    Hatten, Germany
  • 1275.10.49008 Boehringer Ingelheim Investigational Site
    Kiel Kronshagen, Germany
  • 1275.10.49004 Boehringer Ingelheim Investigational Site
    Köln, Germany
  • 1275.10.49010 Boehringer Ingelheim Investigational Site
    Lübeck, Germany
  • 1275.10.49003 Boehringer Ingelheim Investigational Site
    Münster, Germany
  • 1275.10.49006 Boehringer Ingelheim Investigational Site
    Pirna, Germany
  • 1275.10.49013 Boehringer Ingelheim Investigational Site
    St. Ingbert/Oberwürzbach, Germany
  • 1275.10.49001 Boehringer Ingelheim Investigational Site
    Unterschneidheim, Germany
  • 1275.10.49015 Boehringer Ingelheim Investigational Site
    Wangen, Germany
  • 1275.10.39005 Boehringer Ingelheim Investigational Site
    Ancona, Italy
  • 1275.10.39006 Boehringer Ingelheim Investigational Site
    Catania, Italy
  • 1275.10.39009 Boehringer Ingelheim Investigational Site
    Catania, Italy
  • 1275.10.39014 Boehringer Ingelheim Investigational Site
    Catania, Italy
  • 1275.10.39007 Boehringer Ingelheim Investigational Site
    Latina, Italy
  • 1275.10.39012 Boehringer Ingelheim Investigational Site
    Milano, Italy
  • 1275.10.39013 Boehringer Ingelheim Investigational Site
    Milano, Italy
  • 1275.10.39015 Boehringer Ingelheim Investigational Site
    Olbia (OT), Italy
  • 1275.10.39016 Boehringer Ingelheim Investigational Site
    Orbassano (TO), Italy
  • 1275.10.39004 Boehringer Ingelheim Investigational Site
    Palermo, Italy
  • 1275.10.39003 Boehringer Ingelheim Investigational Site
    Pistoia, Italy
  • 1275.10.39008 Boehringer Ingelheim Investigational Site
    Roma, Italy
  • 1275.10.39001 Boehringer Ingelheim Investigational Site
    Sesto San Giovanni (MI), Italy
  • 1275.10.39010 Boehringer Ingelheim Investigational Site
    Siena, Italy
  • 1275.10.39011 Boehringer Ingelheim Investigational Site
    Terni, Italy
  • 1275.10.35104 Boehringer Ingelheim Investigational Site
    Cantanhede, Portugal
  • 1275.10.35112 Boehringer Ingelheim Investigational Site
    Porto, Portugal
  • 1275.10.35103 Boehringer Ingelheim Investigational Site
    Sandim, Portugal
  • 1275.10.35105 Boehringer Ingelheim Investigational Site
    Tornada, Portugal
  • 1275.10.35108 Boehringer Ingelheim Investigational Site
    Valadares, Portugal
  • 1275.10.35101 Boehringer Ingelheim Investigational Site
    Vila Nova de Gaia, Portugal
  • 1275.10.07004 Boehringer Ingelheim Investigational Site
    Chelyabinsk, Russian Federation
  • 1275.10.07006 Boehringer Ingelheim Investigational Site
    Saint-Petersburg, Russian Federation
  • 1275.10.07001 Boehringer Ingelheim Investigational Site
    Saratov, Russian Federation
  • 1275.10.07005 Boehringer Ingelheim Investigational Site
    Saratov, Russian Federation
  • 1275.10.07003 Boehringer Ingelheim Investigational Site
    St. Petersburg, Russian Federation
  • 1275.10.07002 Boehringer Ingelheim Investigational Site
    Yaroslavl, Russian Federation
  • 1275.10.34003 Boehringer Ingelheim Investigational Site
    Barcelona, Spain
  • 1275.10.34004 Boehringer Ingelheim Investigational Site
    Canet de Mar, Spain
  • 1275.10.34008 Boehringer Ingelheim Investigational Site
    Centelles, Spain
  • 1275.10.34009 Boehringer Ingelheim Investigational Site
    L'Hospitalet de Llobregat (Barcelona), Spain
  • 1275.10.34012 Boehringer Ingelheim Investigational Site
    La Roca del Vallès, Spain

Showing the first 100 of 114 sites across 11 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Tinahones FJ, Gallwitz B, Nordaby M, Gotz S, Maldonado-Lutomirsky M, Woerle HJ, Broedl UC. Linagliptin as add-on to empagliflozin and metformin in patients with type 2 diabetes: Two 24-week randomized, double-blind, double-dummy, parallel-group trials. Diabetes Obes Metab. 2017 Feb;19(2):266-274. doi: 10.1111/dom.12814. Epub 2016 Nov 24. PubMed 27762093 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2013, a primary completion of Mar 2015 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2016, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2013
First posted
Jan 29, 2013
Start
Jan 2013
Primary completionActual
Mar 2015
CompletionActual
Mar 2015
Results first posted
Apr 4, 2016
Last update
Apr 4, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01778049
Responsible party
Sponsor
First posted
Jan 29, 2013
Start date
Jan 2013
Primary completion
Mar 2015
Completion
Mar 2015
Results posted
Apr 4, 2016
Last update
Apr 4, 2016

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Empagliflozin · Linagliptin

Start the discussion